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Abstract 
 
Aims: the aim of this review was to evaluate the global prevalence of erectile dysfunction 
(ED); as well as its association with physiological and pathological ageing by examining the 
relationship between ED and cardiovascular disease (CVD), benign prostatic hyperplasia 
(BPH) and dementia. We also aimed to characterise discrepancies caused by use of different 
ED screening tools. 
 
Methods: Embase and Medline were searched to find population-based studies 
investigating the prevalence of ED and the association between ED and CVD, BPH and 
dementia in the general population.  
 
Results: the global prevalence of ED was 3-76.5%. ED was associated with increasing age. 
Use of the IIEF and MMAS derived questionnaire identified a high prevalence of ED in young 
men. ED was positively associated with CVD. Men with ED have an increased risk of all-cause 
mortality OR 95% CI of 1.26 (1.01-1.57) as well as CVD mortality 1.43 (1.00-2.05). Men with 
ED are 1.33-6.24 times more likely to suffer from BPH compared to men without ED and 
1.68 times more likely to develop dementia compared to men without ED.  
 
Conclusion: ED screening tools in population-based studies are a major source of 
discrepancy. Non-validated questionnaires may be less sensitive than the IIEF and MMAS 
derived questionnaire. ED constitutes a large burden on society given its high prevalence 
and impact on quality of life and is also a risk factor for CVD, dementia and all-cause 
mortality.  
Introduction 
 
Erectile dysfunction (ED) represents an increasing health concern causing significant impact 
on the quality of life of men globally. It is estimated that 322 million men worldwide will be 
affected by ED by 2025, an increase from 152 million men in 19951. This is also reflected by 
a growing economic burden. Annual expenditure in the USA on ED was $330 million in 2000, 
compared to $185 million in 1994 (excluding pharmaceutical costs)2. ED also significantly 
affects the quality of life of men’s partners. Partners of men with ED experience lower 
sexual satisfaction, correlated to the degree of ED in their partner3.  
 
The physiology of achieving and maintaining an erection involves integration of 
psychological, hormonal, neurological and vascular pathways. ED is therefore a symptom of 
a wide range of pathologies. It is often classified into organic (endocrine, neurological, 
vascular and structural) and psychogenic aetiologies, however both are often heavily 
interlinked and difficult to discern4. 
 
The principal risk factor associated with ED is age, and the increasing prevalence of ED is 
linked to the global ageing population4. Other risk factors independently associated with ED 
include diabetes, cardiovascular disease (CVD), depression and benign prostatic hyperplasia 
(BPH)5,6. The presence of ED has also been found to be a predictor of cardiovascular disease, 
dementia and all cause mortality7,8. 
 
The prevalence of ED is difficult to estimate due to the range of definitions of ED used. The 
National Institutes of Health (NIH) consensus development conference in 1993, defined ED 
as ‘the inability to achieve or maintain an erection sufficient for satisfactory sexual 
performance’53. The challenge remains however, to measure ED accurately in population-
based studies, particularly given the subjective nature of this definition.  
 
The International Index of Erectile Function (IIEF) is a self-administrable questionnaire 
developed to detect treatment effects in clinical trials55. It consists of 15 items categorised 
by 5 domains of sexual functioning and therefore represents significant respondent burden. 
An abridged version of the IIEF was therefore, subsequently developed, the IIEF-5 or Sexual 
Health Inventory for Men (SHIM), with high sensitivity and specificity to detecting ED in 
clinical trial subjects for sildenafil citrate (Viagra)56. Derby et al. sought to develop a simple 
tool for assessing ED in population-based studies. A single item questionnaire was created 
and tested against the IIEF in the Massachusetts Male Aging Study (MMAS), a prospective 
cohort study from Boston, USA. A high negative agreement between the MMAS-derived 
questionnaire and IIEF was found34. The IIEF and MMAS-derived questionnaires are the 
most common tools used for identifying ED in population based-studies, however other 
tools still exist and are used frequently. This remains a major limitation to the translatability 
of study results. 
 
 
 
 
 
 
 
 
Methods 
 
A search of Embase and Medline was conducted using the search terms: ‘[impotence or 
erectile dysfunction] and [general population or community-based or population-based]’ to 
find studies relating to the global prevalence of ED. To review the association between 
cardiovascular disease and ED the same databases were used to search ‘[erectile 
dysfunction or impotence and cardiovascular disease or atherosclerosis and general 
population or population-based]’. For the association between ED & BPH, search terms used 
were: ‘[Erectile dysfunction or Impotence] and [benign prostatic hyperplasia or lower 
urinary tract symptoms] and [general population or population-based]’. Finally, the 
association between ED and dementia was reviewed by using search terms ‘[Impotence or 
erectile dysfunction] and dementia and [general population or population-based]. Filters 
used included English language, title and abstract, human and male. 
 
Initial selection of studies was performed independently, based on title, followed by 
screening of the full text. Articles were excluded if there was no information on ED 
prevalence or the association between ED and CVD, BPH or dementia, the study population 
was not representative of the general population, there was no original data or the full text 
was not available.  
 
 
 
 
 
Results 
 
Study Selection 
The initial search for studies on the global prevalence of ED yielded 1,501 results, after 
duplicates were removed and filters applied (n=799) 702 records were screened. 635 
articles were excluded based on title and 67 full articles were then assessed for eligibility. 26 
studies were excluded due to lack of original data (n=8), specific study population (n=3), 
abstract only (n=3), text not available (n=1), no information on ED prevalence (n=4), unclear 
methods (n=7).  
Initial search results for the association of ED and CVD yielded 220 articles, after removal of 
duplicates and filters applied (n=117), 103 titles were screened and 43 articles selected for 
full text review. 26 studies were subsequently excluded due to lack of original data (n=4), 
abstract only (n=9), text not available (n=2), specific study population (n=4), irrelevant (n=7). 
The association between ED and BPH gave 95 results initially. After deduplication and 
addition of limits, 44 titles remained. 20 relevant articles were chosen by screening titles of 
which 8 were excluded due to study population (n=2), abstract only (n=2), full text not 
available (n=1) and no information on the association between ED and BPH (n=4). The 
search for the association between ED and dementia resulted in 6 articles, after duplicates 
were removed (n=2), 4 article titles were screened of which only one study was relevant.  
 
Use of Questionnaires 
Out of 41 studies extracted, 15 (36.6%)  used the IIEF, 10 (24.4%) used the MMAS derived 
questionnaire and 16 (39.0%) used other tools.   
 
ED Prevalence 
Table 1 displays the prevalence of ED assessed by the IIEF, IIEF-5 or IIEF variants. The overall 
global prevalence was 13.1-71.2% 12-26. The prevalence by continent was as follows, North 
America: 20.7%16, Europe: 16.8-65.4%21, 22, 25, 26, Oceania: 40.3-42%12,15, Asia: 13.1-71.2%13, 
17, 18, 20, 23, 24, Africa: 24-58.9%14,19. All studies demonstrated a trend of increasing ED 
prevalence with increasing age 12-15, 17-25. Young men (<40 years old) had an exceptionally 
high prevalence of ED15, 18, 22, 23. There was no apparent trend in ED severity. Wu et al. 
compared self-reported ED prevalence to ED as determined by the IIEF-5 and found a lower 
prevalence of self-reported ED compared to IIEF-5 defined ED (13.1%, and 26.0% 
respectively) in all age groups 20.   
 
The global prevalence of ED as assessed by the MMAS-derived self-assessment was 15.5-
69.2%27-36 (Table 2). The prevalence of ED by continent was 22.0-57.8%31,34,36, 15.5-55.2%28-
30, 33, 35, 17.2%29, 60.6927, 22.4-69.2%29, 32, for North America, South America, Europe, 
Oceania and Asia, respectively. The prevalence of ED increased with increasing age where 
the study population was over 40 years old28, 30-33. 9.1-49.9% of men under 50 years old30-33 
were affected compared to 54.9-94.7% men over 70 years old 31,32. Martins et al. studied a 
young (18-40 years) population of men in Brazil and found a higher prevalence of ED 
amongst 18-25 year olds (35.6%) compared to 26-40 year olds (30.7%)28. The prevalence of 
ED was inversely associated with ED severity, 25.1-36.7%, 8.5-25.0%, 1.3-16.77% had mild, 
moderate and severe ED, respectively27, 30, 32-36. Derby et al. measured ED prevalence using 
both IIEF and the MMAS self-assessment methods. The overall and moderate-severe 
prevalence of ED was the same using both methods34.  
The global prevalence of ED as measured by all other questionnaires was 3-76.5%37-52 (Table 
3). The prevalence by continent was 22-46.3%42, 46, 49, 14%49, 10-76.5%37,38,40, 45, 49, 50, 52, 
49.4%47, 8-65%39, 40, 41, 43, 44, 48, 53.6%51 for North America, South America, Europe, Oceania, 
Asia and Africa, respectively. The prevalence of ED increased with increasing age38, 40-44, 48, 49, 
52. There was no apparent trend in ED severity throughout all age groups 40, 41, 45, 46, 51, 52. 
 
ED and Cardiovascular Disease 
Table 4 describes the association between CVD and ED. When compared to men without 
ED, men with ED were at increased risk of ischaemic heart disease (1.08-1.87)59, 60, 64, heart 
failure (5.19-8.00)64,hypertension (0.89-3.60) 25, 35, 47, 60, 63, dyslipidaemia (1.14-5.48) 47, 59, 60, 
peripheral vascular disease (0.93-2.37) 60, 64, cerebrovascular accident (1.43-3.30) 47, 60, 
angina (1.26)21, metabolic syndrome (1.35-1.52)68, and diabetes (0.58-8.94) 21, 25, 35, 47, 59, 63. 
The risk of CVD was positively associated with severity of ED35, 64, 68 and increasing age25. The 
prevalence of CVD was higher in persons with ED49, 61, 62 and this was correlated with ED 
severity61, 66, 67, 70. The incidence of CVD events per 100 person years in men with normal 
erectile rigidity was 5.1 (95% CI 4.2-6.1) compared to reduced rigidity 10.1 (95% CI 7.4-13.8) 
and severely reduced rigidity 19.0 (95% CI 11.5-31.5)70.  
Men with ED also had an increased risk of all-cause mortality OR 95% CI 1.26 (1.01-1.57) as 
well as CVD mortality 1.43 (1.00-2.05)66. Only one study found no significant increase in 
prevalence of DM, HTN, CVD and DLM in persons with ED28. 
 
ED and Benign Prostatic Hyperplasia  
Table 5 summarises our findings on the association between ED and BPH in the general 
population. Men with ED are 1.33-6.24 times more likely to suffer from BPH compared to 
men without ED 17, 22, 30-32, 35, 62, 72, 74, 76. Prevalence of ED and BPH ranged from 5.2-40% 73, 75 
and prevalence was positively associated with increasing age73. Risk of BPH and ED was also 
correlated to BPH severity; men with severe BPH (IPSS ≥20) were 5.86-6.24 times more 
likely to suffer from ED compared to men with moderate BPH (IPSS 8-19) 1.7-4.4130-32. 
Similarly, prevalence of BPH and ED was associated with ED severity, prevalence of BPH in 
men without ED was 10% compared to 16%, 16%, 23% and 26% for mild, mild-moderate, 
moderate and severe ED, respectively35, 62. 
 
ED and dementia 
Only one study was found which investigated the association between ED and dementia in 
the general population. Yang et al. conducted a longitudinal cohort study of 4,153 ED cases 
at baseline and 20,765 matched controls randomly selected from the National Health 
Insurance Research Database of Taiwan.  Over the 7 year follow-up period, 2.5% of cases 
developed dementia compared to 1.5% of controls. Participants with ED were 1.68 times 
more likely to develop dementia compared to controls (HR 1.68 [95% CI = 1.34–2.10) 
P < 0.0001]82.  
 
 
 
Discussion 
The current review identified that the global prevalence of ED was 13.1-71.2%, 15.5-69.2% 
and 3-76.5% as determined by studies using the IIEF/ IIEF-5, the MMAS-derived 
questionnaire or other questionnaires, respectively.  
 
Global Prevalence 
The range of ED prevalence has been found to vary widely, which may be reflective of 
differences in study population ages. Martins et al., studied 18-40 year olds in Brazil and 
found an overall prevalence of 35.0% ED, whereas Moreira et al. studied 40-70 year olds in 
Brazil as well and found an overall prevalence of 45.9% ED 28, 33. The variety of definitions 
and assessment methods of ED undoubtedly also impact the range of ED prevalence. The 
global prevalence of ED determined by the IIEF/ IIEF-5 and MMAS derived questionnaire are 
relatively similar (13.1-71.2% and 15.5-69.2%, respectively), in comparison to that 
determined by studies using other questionnaires (3-76.5%). Pooled results revealed the 
highest prevalence was found in Europe (10-76.5%), Asia (8-71.2%), Oceania (40.3-60.69%), 
Africa (24-58.9%), North America (20.7-57.8%) and the lowest prevalence was found in 
South America (14-55.2%). The cause of the geographical disparities in ED prevalence is 
likely to be multifactorial. Genetic, environmental and lifestyle factors are likely to be 
involved. The main risk factors associated with ED include age, comorbidities (diabetes, 
cardiovascular disease, obesity, prostate cancer and depression and anxiety treatment), 
lifestyle factors such as heavy alcohol consumption and smoking were also positively 
associated with ED16, 18, 19, 21, 27. Single, separated or divorced men were also at increased 
risk, as well as men who are unemployed or of low socio-economic status15, 16. Furthermore, 
due to the sensitive nature of the topic, cultural factors affecting perceptions may influence 
reporting of ED.  
 
ED and Age 
Age as a risk factor for ED was universal across all studies. A linear relationship between 
increasing ED prevalence and increasing age was also seen in all studies, regardless of the 
ED assessment method used12-15, 17-25, 28, 30-33, 38, 41-45, 49, 50, 53. Physiological ageing processes 
mediating vascular changes in the penis have been implicated, however cardiovascular 
comorbidities such as diabetes and hypertension appear to expedite and exacerbate the 
process58.  In studies where young men were included in the study population, young men 
were found to have an exceptionally high prevalence of ED 15, 18, 22, 23, 28. This was the case 
for studies using the IIEF, IIEF-5 or MMAS-derived questionnaire as an ED measurement 
tool, but not those using other questionnaire types 42, 45, 49, 50, 51. The relatively high 
prevalence of ED in young men may be due to psychological factors such as anxiety related 
to sexual inexperience, performance anxiety as well as life stressors related to 
independence and joining the workforce. Organic causes for erectile dysfunction, however, 
should be excluded in young men presenting with ED59.It is likely that the questionnaires 
used by Lau, Tan, Rosen and Hendrickx (table 3) are not as sensitive as the IIEF, IIEF-5 or 
MMAS-derived questionnaires at detecting ED in young persons. The questionnaire used by 
Hendrickx et al., specifically applies to men who are having sexual intercourse, however a 
proportion of this age group may not yet be engaging in sexual intercourse which could lead 
to under-reporting ED. The questionnaire used by Rosen et al. also seems tailored to well-
educated men who have had previous sexual experience and therefore may not be sensitive 
to detecting ED in sexually inexperienced and less educated men.  Lau et al. simply asked 
participants to answer ‘yes/no’ to the question ‘do you have erectile difficulties?’, young 
men may be less willing to identify with this question positively compared to their older 
counterparts, which may lead to under-reporting ED in this age-group.  
 
 
 
ED Severity 
In studies using the MMAS-derived questionnaire there was an inverse trend between ED 
prevalence and severity. 25.1-36.7%, 8.5-25.0%, 1.3-16.77% had mild, moderate and severe 
ED, respectively27, 30, 32-36. This trend was not seen in studies using the IIEF/ IIEF-5 or other 
questionnaires. Firstly, it is difficult to compare severity measured because the IIEF/ IIEF-5 
traditionally classifies severity into four categories: mild, mild-moderate, moderate and 
severe; whereas the MMAS-derived questionnaire uses three categories: mild, moderate 
and severe. Furthermore, the IIEF/ IIEF-5 severity is calculated on a points-based system for 
answers chosen by subjects. Conversely, the MMAS-derived questionnaire requires men to 
classify themselves subjectively as being mild, moderate or severely impotent. Our results 
show men are more likely to self-report themselves as having mild ED using the MMAS 
assessment compared to the IIEF/ IIEF-5 or other questionnaires. This may be due to 
perceptions or embarrassment surrounding admitting to having ED and its severity as part 
of certain questionnaires; whereas the points-based IIEF/ IIEF-5 system provides a degree 
‘blinding’, as subjects are not aware of how their answers correlate to ED severity. Wu et al., 
compared the prevalence of ED defined by the IIEF-5 and self-reported by answering yes or 
no to the question ‘do you think you have ED?’. 26.0% were found to have ED using the IIEF-
5, compared to 13.1% who self-reported having ED. 18.8% of those who self-reported not 
having ED were subsequently found to have ED as defined by the IIEF-5 and 26.2% of those 
who self-reported ED did not class as ED according to the IIEF-520. This is further evidence 
that self-reported data may a less sensitive measure of ED in population-based studies.   
 
 
 
Association between ED and Cardiovascular Disease 
There is a wealth of evidence for the association between ED and CVD. This review 
identified an increased prevalence and incidence of CVD, including HTN, MI, IHD, angina, 
stroke/ TIA, arteriosclerosis, HLD, HCL, PVD, MS and DM in study participants with ED. One 
study found no significant association between ED prevalence and diabetes, hypertension, 
dyslipidaemia or CVD28. Martins et al performed a cross-sectional observational study on 
men aged 18-40 years old. The relatively young population studied, likely explains the lack 
of significant association found. Both ED and CVD are associated with increasing age and 
therefore the effects of the association between ED and CVD may not be evident in this age 
group28.  
 
The association between hypertension, dyslipidaemia and ED remains controversial. Lahoz 
et al. found no significant association between ED and HTN, elevated cholesterol or 
triglycerides63. Equally, de Boer et al found the risk of HTN in ED patients to be 0.83 (95% CI 
0.56-1.25)21. Use of anti-hypertensives and cholesterol-lowering drugs are ubiquitous in the 
general population, this is likely to be a strong confounding factor when examining HTN and 
dyslipidaemia. ED may also be a side-effect of these medications, however this is an area 
which requires further research and is beyond the scope of this review.  
 
ED as a Risk Marker for CVD 
The majority of studies reviewed were cross-sectional population studies and therefore the 
nature of the association between ED and CVD is difficult to interpret. The Massachusetts 
Male Ageing Study (MMAS), however, is a longitudinal cohort study of randomly selected 
men between 40-70 years old. Participants were surveyed at 3 points in time and followed 
up for 16.2 years. The CVD incidence for men with moderate-complete ED was 17.9 (95% CI 
14.1-22.6) per 1,000 person-years compared to a CVD incidence of 12.5 (95% CI 10.8-14.3) 
for men with none-minimal ED (p<0.05). Frequency of sexual activity was inversely 
associated with CVD incidence68. Using data from the same study, Araujo et al. found an 
increased risk of all-cause mortality in men with ED as well as an increased risk of CVD death 
in men with moderate-severe ED 1.87 (95% CI 1.32-2.64) compared to men with none-
minimal ED. There was a dose-dependent association between risk of CVD death and ED 
severity66. The authors postulate that sexual activity being physical activity may in itself be 
cardio protective. Additionally, men engaging in frequent sexual activity may also be likely 
to have intimate relationships which offer support, decrease stress and therefore improve 
cardiovascular health68. Schouten et al. also conducted a longitudinal community-based 
study, the Krimpen study, to examine general health and genitourinary problems of men 
aged 50-75 years71.Reduced erectile rigidity was associated with an increase in CVD event 
incidence in a dose-response fashion. HR for CVD events and reduced erectile rigidity was 
2.0 (95% CI 1.4-2.7) and 3.8 (95% CI 2.0-7.3) for severely reduced erections. ED is therefore 
likely to be a ‘risk marker’ for CVD, rather than a risk factor, reflecting the presence of 
vascular endothelial dysfunction and atherosclerosis which predispose cardiovascular 
morbidity and mortality68.  
 
ED and Benign Prostatic Hyperplasia 
The prevalence of ED and concurrent BPH is high, 5.2-40% 72, 74 and men with ED are 1.33-
6.24 times more likely to suffer from BPH compared to men without ED 17, 22, 30, 31, 32, 35, 61, 71, 
73, 75. The prevalence of ED and BPH increased with age, as expected as both conditions are 
associated with age. Furthermore, shared risk factors between ED and BPH, such as 
atherosclerosis and diabetes, are also associated with ageing76. The bidirectional dose-
response relationship between ED and BPH prevalence together with their common risk 
factors suggest a shared pathophysiology, however this has yet to be elucidated. It is likely 
that psychological factors are a strong contributor. Kim et al. found that men with lower 
urinary tract symptoms (LUTS) had a decreased frequency and enjoyment in sexual activity 
as well as lower sex life satisfaction due to urinary symptoms72. Men with LUTS may 
therefore experience sexual performance anxiety and aversion of sexual activity which may 
contribute to the development of ED. Evidence is limited on the underlying link between ED 
and BPH, however, one possible explanation is impaired nitric oxide (NO) or nitric oxide 
synthase (NOS) production in bladder, prostate and penile smooth muscle. This may impair 
smooth muscle functioning which is involved in bladder compliance, contractility and 
vasodilation of erectile tissues76. Another proposed hypothesis for the pathophysiology of 
ED and BPH is pelvic atherosclerosis. Hypoperfusion of the bladder, prostate and penis may 
cause fibrosis of smooth muscle resulting in LUTS and ED76.  
 
The relationship between ED & LUTS is important to consider in clinical practice as many 
therapies for BPH may cause or worsen ED as a side effect, for example finasteride or 
prostate surgery. Interestingly, Sairam et al. found that men with ED and LUTS treated with 
sildenafil experienced an improvement in LUTS as well as erections77.  Men presenting with 
LUTS and ED may benefit from an initial phosphodiesterase inhibitor trial.  
 
ED and Dementia 
Evidence of the association between ED and dementia in the general population is limited. 
Previous cross-sectional studies have shown an association between ED & dementia, 
however due to study design it was not possible to elucidate a directionality to the 
relationship79, 80. Yang et al. have demonstrated a greater prevalence of dementia amongst 
men with long-standing ED (2.5%) compared to controls (1.5%) and that men with ED are 
1.68 times more likely to develop dementia81. Moore et al also found that men with ED had 
poorer cognitive function compared to those without ED82. The pathophysiology underlying 
the relationship between ED and dementia is likely to be complex; vascular, neuronal and 
psychological factors may all be implicated. Alzheimer’s and vascular dementia, however are 
strongly associated with CVD risk factors. Endothelial dysfunction is thought to be the 
common denominator82. ED may therefore be a culmination of subclinical CVD risk factors 
which is a risk marker for both cardiovascular disease and dementia.   
 
 
 
Limitations 
The review is limited by the studies included, no non-English language studies were 
included. This may lead to certain bias, nevertheless, data from all geographical regions of 
the world has been presented here. Data is also limited by varying definitions and 
measurements of ED in population-based studies which make certain studies incomparable. 
Initial data extraction involved excluding articles based on title, although only 
unambiguously irrelevant articles were removed in this way, there is a possibility worthy 
articles were missed.  
 
 
 
Conclusion 
There is widespread use of unvalidated assessment tools, despite the existence of 
developed items such as the IIEF and MMAS-derived questionnaire.  
The global prevalence of ED is high and represents a significant burden on the quality of life 
of men and their partners. ED is not simply a consequence of physiological aging, but also a 
symptom of pathology such as CVD, BPH and dementia. ED has been identified as a risk 
marker for cardiovascular morbidity and mortality as well as all-cause mortality. Widespread 
and early detection of ED may, therefore, improve primary prevention of CVD and mortality, 
as well as improving quality of life by treating ED itself. ED is also strongly associated with 
BPH, however the aetiology of the relationship remains to be elucidated. ED has also been 
found to predict development of dementia, early cognitive testing may therefore be 
warranted in certain ED patients. Young men are also affected by ED, putatively of 
psychological aetiology. Due to the sensitive nature of the topic, physicians should consider 
screening for ED in at risk patients, as information may not be volunteered.  
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Table 1. Global prevalence of ED measured by the International Index of Erectile Function and variants.  
 
Author Country ED Measurement Study size 
Prevalence rates (%) (95% CI) 
Age (y) Overall Mild 
Mild-
Moderate 
Moderate Severe/complete 
Quilter12 New Zealand IIEF-5 562 
40-70 42 
21.9 10.3 5.9 4.1 
40-49 23.6 
50-59 37.9 
60-69 59.4 
Zhang13 China IIEF-5 5,210 
≥40 40.56 
    
40-49 18.08 
50-59 23.56 
60-69 48.37 
≥70 81.60 
Oyelade14 Nigeria IIEF-5 241 
30-80 58.9 
47.2  11.3 41.5 ≤49 51.9 
≥50 72.3 
Chew15 Australia IIEF-5 1,580 
20-80 40.3 
11.30 5.3 2.60 21.20 
20-29 15.70 
30-39 8.70 
40-49 12.90 
50-59 31.60 
60-69 52.40 
70-79 69.4 
≥80 68.2 
Kupelian16 USA IIEF-5 2,301 30-79 20.7 26 12 6 3 
Mariappan17 Malaysia IIEF-5 344 
≥40 71.2 
25.3  34.9 11.1 
40-49 43.3 
50-59 83.3 
60-69 94.1 
≥70 94.9 
Tan18 Singapore IIEF-5 729 
≥30 51.3 
23.2 
(20.1-26.2) 
 8.8 
(6.7-10.8) 
19.3 
(16.5-22.2) 
30-39 47.10 (35.3-48.1) 
40-49 42.8 (37.1-48.1) 
50-59 64.00 (55.2-72.8) 
60-69 77.4 (67-87.8) 
>70 90.0 (80.7-99.3) 
Pallangyo19 Tanzania IIEF-5 441 
≥18 24 
8.50 22.60 37.80 31.10 18-39 10.6 
≥55 37.0 
Wu20 Taiwan 990 >40 26.01 , 13.12 23.81  1.4 1 0.8 1 
IIEF-51 & self-
reported2 
40-49 16.011 , 5.322 
50-59 25.411 , 15.642 
60-69 42.751 , 21.012 
≥70 54.791 , 27.72 
De Boer21 The Netherlands IIEF-5 & LIST3 2,117 
≥18 16.8 (15.2-18.4) 
5.9  3.6 6.9 
18-30 4 (1.8-6.3) 
31-40 5.6 (3.5-7.6) 
41-50 13.7 (10.8-16.5) 
51-60 23.7 (19.5-27.8) 
61-70 40.0 (32.9-47.0) 
71-80 41.9 (33.6-50.2) 
>80 33.3 (17.9-48.7) 
Korneyev22 Russia IIEF 1,083 
20-77 48.9 
34.6  7.2 7.1 
<21 36.4 
21-30 28.9 
31-40 37.4 
41-50 52.2 
51-60 63.7 
61-70 76.6 
71-80 87.0 
Sathyanarayana2
3 India IIEF 742 
>18 15.77 
19.7 42.7 28.2 9.4 
18-25 13.00 
26-30 8.6 
31-40 9.9 
41-50 16.9 
51-60 27.6 
61-65 15.6 
66-75 14.3 
Ng24 China 
IIEF (question 
item 15 only) 
1,506 
26-70 36.7 ( 33.7-39.7) 
 
26-30 18.3 (11.1-25.4) 
31-40 28.6 (23.5-33.6) 
41-50 37.9 (32.3-43.5) 
51-60 47.3 (40.1-54.5) 
61-70 61.1 (51.1-71.0) 
Mak25 Belgium 
IIEF4 / IIEF item 
155 
799 
40-70 
43.44; 65.4 (62.0-
68.7)4 
11.24; 25.8 
(22.8-29.1)5 
 
2.94; 27.6 
(23.9–30.2)5 
1.84; 12.7 
(10.5–15.2)5 
40-49 
11.24; 42.8 (36.5-
49.3)5 
50-59 
18.04; 69.4 (63.2-
75.1)5 
60-69 
18.14; 80.5 (75.4-
84.7)5 
Dunn26 UK Adapted IIEF6 789 18-75 
26 (23-30)7; 39 
(35-42)8 
    
1 IIEF-5   
2  Self-reported ED assessed by single question: ‘do you think you have ED? Yes/ No.’ 
3 Leidse Impostence Scale Test (LIST) 
4 IIEF used in sexually active men 
5 IIEF item 15 was used as a surrogate measure for men not sexually active in past one month: ‘how do you rate your confidence that you could get and keep an erection? Very high confidence= 
no ED, high confidence most times= mild ED, mod-low confidence= moderate ED, very low/ never achieving =complete ED’ 
6 2 items from the IIEF were used to measure ED: 1. ‘Have you ever had any difficulties initiating an erection before intercourse 2. Have you ever had any difficulties maintaining an erection 
throughout intercourse’ If both were present then the subject was said to have ED. 
7 in the last 3 months 
8 over lifetime 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2. Global prevalence of ED measured by the MMAS-derived self-assessment. 
Author Country ED Measurement Study size Prevalence rates (%) (95% CI) 
Age (y) Overall Mild Moderate Severe/complete 
Weber27 Australia MMAS self-assessment 101, 674 ≥45 60.7 (60.4-61.0) 25.14 
(24.9-25.4) 
18.79 
(18.6-
19.0) 
16.8 
(16.5-17.0) 
Martins28 Brazil MMAS self-assessment 1,947 18-40 35.0 
   
18-25 35.6 
26-40 30.7 
Nicolosi29 Japan MMAS self-assessment  
2417  
  
40-70 34.5 
   
Malaysia 22.4 
Italy 17.2 
Brazil 15.5 
Moreira30 Brazil MMAS self-assessment 602 40-70 39.5 25.1 13.1 1.3 
40-50 30.8 
50-60 43.4 
60-70 56.7 
Laumann31 USA MMAS self-assessment 2,173 ≥40 22.0 (19.4-24.6) 
   
40-49 9.1 ((5.9-12.2) 
50-59 15.2 (11.3-19.1) 
60-69 29.4 (22.8-35.9) 
≥70 54.9 (46.9-62.8) 
Akkus32 Turkey MMAS self-assessment 1,982 ≥40 69.2 33.2 27.5 8.5 
40-49 49.9 
50-59 74.8 
60-69 86.3 
≥70 94.7 
Moreira33 Brazil MMAS self-assessment 342 40-70 45.9 33.9 8.5 3.5 
40-50 35.40 
50-60 48.90 
≥60 85.40 
Derby34 USA MMAS self-assessment1 & 
IIEF2 
5051; 2542 40-69 50.0 (45-54)1; 50.0 (42-
57)2 
 
25.0 (20-29)1; 25.0 (19-32)2 
Morillo35 Colombia MMAS self-assessment 622 ≥40 52.8 (48.9-56.7) 32.3 
(25.8-38.7) 
16.4 
(9.3-
23.5) 
3.6 
(0-11.9) 
Ecuador 670 52.1 (48.3-55.9) 31.8 
(25.2-38.1) 
16.1 
(9.2-
23.0) 
2.5 
(0-9.9) 
Venezuela 654 55.2 (51.4-58.9) 36.7 
(30.6-42.8) 
15.8 4.1 
(0-11.6) 
(8.7-
22.8) 
Londono36 USA MMAS self-assessment 37,712 45-69 57.80 28.72 20.53 8.55 
 
 
Table 3. Global prevalence of ED measured by other questionnaires 
Author Country ED Measurement Study size Prevalence rates (%) (95% CI) 
Age (y) Overall Mild  Moderate Severe/complete 
Parish40 China 2-item 
Questionnaire8 
(≥2 months) 
1,261 20-64 8.0 (6.0-10.0) 
  
Shiri41 Finland 2-item 
Questionnaire8 
1,941 50 67.0    
75 88.5 
Ansong42 USA 2-item 
Questionnaire9 
1,408 50-76 46.3 
   
50-54 26.0 
   
55-59 34.9 
60-64 46.9 
65-69 57.8 
70-76 69.4 
Chen43 Taiwan Checklist: ED 
yes/ no? 
1,002 40-83 17.7 
   
40-50 8.2 
51-60 17.9 
61-70 27.2 
≥71 34.4 
Lau44 China Questionnaire: 
erection 
difficulties yes/ 
no? 
1,516 18-60 9.6 
   
18-19 0.8 
20-29 4.5 
30-39 8.9 
40-49 10.1 
50-59 23.5 
Buvat45 France Questionnaire: ≥2 
months erectile 
difficulties,- no/ 
occasionally/ 
sometimes/ 
frequently 
750 40-80 15.0 (12.2-18.2) 6.0 (4.2-8.3) 7.6 (5.6-10.1) 1.4 (0.6-2.7) 
Southern Europe 
1,500 
11.7 (10.2-13.4) 4.3 (3.4-5.5) 5.3 (4.2-6.5) 1.9 (1.3-2.7) 
Northern Europe 
3,250 
13.1 (11.7-14.6) 5.0 (4.1-6.0) 5.3 (4.4-6.4) 2.7 (2.0-3.4) 
Lauman46 USA Questionnaire: ≥2 
months erectile 
difficulties,- no/ 
occasionally/ 
sometimes/ 
frequently 
742 40-80 22.5 (19.6-25.7) 9.6 (7.6-12.0) 5.9 (4.3-7.9) 6.5 (4.8-8.5) 
Hyde47 Australia Questionnaire: 
‘ever had trouble 
gaining/ 
maintaining an 
erection?’ 
3,274 75-95 49.4 (47.7-51.1) 
   
Tan48 China,Japan,Korea,
Malaysia,Taiwan 
Questionnaire10 10, 934 Age   
 
 
 
 
 
 
 
 
20-75 3-14 
20-29 1-7 
30-39 1-6 
40-49 1-6 
50-59 6-21 
60-75 11-26 
Rosen49 USA, UK, 
Germany, France, 
Italy, Spain, 
Mexico, Brazil 
Questionnaire11 27,839 20-75 16    
20-29 8 
30-39 11 
40-49 15 
50-59 22 
60-69 30 
70-75 37 
Schouten50 The Netherlands International 
Contience Society 
Male Sex 
Questionnaire12 
1,643 50-75 40 
   
Berrada51 Morocco Pfizer Cross-
National Study of 
the Prevalence 
and Correlates of 
ED 
Questionnaire13 
646 ≥25 53.6 37.5 15.0 1.1 
Hendrickx52  Belgium  Sexual 
Functioning 
Scale14 
696 14-80 22.5 (19.4-29.5) 15.6 (12.9-18.3) 3.2 (1.9-4.5) 3.7 (2.3-5.1) 
14-34 0.9 (0-2.1) 
35-49 3.0 (0.8-5.2) 
50-64 11.0 (6.2-15.8) 
65-80 41.3 (30.2-52.4) 
Korfage37, 38 The Netherlands 
 
Dutch module on 
sexual activity6 
3,299 55-74 19.0    
3,810 57-78 19.0 
58-61 12.0 
62-64 14.6 
65-67 18.4 
68-70 21.9 
71-78 26.3    
Li39 China (Hong Kong) The Danish 
Prostatic 
Symptoms Score7 
201 50-80 50    
Singapore 204 53 
Malaysia 250 59 
Philippines 250 65 
Thailand 250 65 
6 ‘ED was defined as being sexually inactive because of erectile problems or being sexually active but experiencing problems with getting or maintaining an erection, even when erectile aids 
were used’ 
7 'Can you get an erection? 1. yes with normal stiffness 2. yes with a slight reduction in stiffness 3. Yes with a big reduction in stiffness 4. No, I cannot get erection' 
8 2 item questionnaire: 1. do you experience difficulty achieving erection to initiate intercourse, 2. do you have difficulty maintaining erection during intercourse ≥2 months 
9 2 Item questionnaire: 1.’Have you experienced erectile dysfunction (impotence) within the past 6 months? Have you sought treatment for erectile dysfunction (impotence)?’ 
10 Questionnaire: “Which of the following best describes your erection difficulty (or the difficulty you used to have)?”: (i) I get no erection at all; (ii) I have difficulty getting a sufficiently good 
erection; (iii) I get satisfactory erections, they just don't last long enough; (iv) The problem is with ejaculation, not with my erection, or (v) other.  
11 Questionnaire: Erection difficulties? ‘ (A) seen a doctor, pharmacist or therapist about it; (B) tried any kind of remedy, with or without prescription; (C) not done anything about it; or (D) 
never had it.’ 
12 Do you get erections?” were recoded “ED” if the participants reported “yes, with reduced rigidity” or “yes with severely reduced rigidity” or “no, no erections possible” or “no, never had.” 
13 Pfizer Cross-National Study of the Prevalence and Correlates of ED Questionnaire13 
14 Sexual Functioning Scale: <6 months erectile difficulties initiating erection sufficiently rigid for penetration or maintaining erection throughout intercourse: mild/ moderate/ severe.   
  
Table 4. The association between ED and cardiovascular disease 
Author Country ED 
Measurment 
CVD 
measurement 
Study 
Size 
Sampl
e Age 
Findings (OR/ HR 95% CI) 
Martins2
8 
Brazil MMAS 
questionnaire 
Self-reported 1,947 18-40 No increase in ED prevalence associated with diabetes, hypertension, cardiovascular disease, and 
dyslipidemia 
 
Araujo65 USA MMAS 
questionnaire 
NDI 1,709 40-70 All-cause mortality: 1.3 (1.0–1.6); CVD mortality: 1.4 (95% CI, 1.0–2.1) 
Araujo66 USA MMAS 
questionnaire 
Self-reported, 
NDI 
1,057 40-70 CVD incidence: 1.4 (1.1-1.9) 
Bai59 China CIEF-51 Self-reported 2,226 20-86 Heart Disease 3.7 (2.9-4.7) 
DM 3.5 (2.4-5.2) 
DLM 2.1 (1.4-3.0) 
Chew60 Australia IIEF-5 Self-reported 1,580 ≥20 HTN 1.5 (1.1-2.1) 
IHD 1.9 (1.2-3.0) 
Stroke 3.3 (1.1-8.1) 
DLM 1.1 (0.8-1.6) 
PAD 2.4 (0.9-6.3) 
Hyde47 Australia ‘Difficulty 
gaining or 
maintaining an 
erection?’ 
Self-reported, 
hospital record 
3,274 75-95 CAD 1.5 (1.2-2.0) 
Stroke/TIA 1.4 (0.9-2.2) 
HTN 1.4 (1.1-1.7) 
DM 1.6 (1.1-2.3) 
DLM 1.1 (0.9-1.4) 
De 
Boer21 
The 
Netherlands 
IIEF-5 & LIST Self-reported 2,117 ≥18 DM 1.7 (1.0–3.1) 
HTN 0.8 (0.6–1.3) 
Arteriosclerosis 1.2 (0.5–3.1) 
Angina pectoris 1.3 (0.5–3.0) 
MI 1.6 (0.7–3.7) 
Stroke 0.4 (0.1–1.5) 
CVD9 1.7 (1.2–2.4) 
Chao63 Taiwan IIEF Self-reported, 
blood tests 
238 >40 DM 8.9 (4.7—17.0)** 
HTN 3.6 (2.0-6.5)** 
TG abnormal 2.8 (1.3-5.9)* 
HDL abnormal 5.5 (3.1 -- 9.8)** 
Shabsigh
61 
USA, UK, 
Germany, 
France, Italy, 
Spain 
 
Questionnaire2 Self-reported 28,691 20-75 ED 
CVD % Mild Moderate Severe 
HTN  
25 
 
42 
39 
HCL   38 
25 35 
Angina  
7 
 
16 
34 
DM  
8 
 
16 
24 
MI/ 
surgery 
 
7 
 
13 
29 
Arterios
clerosis 
 
6 
 
10 
13 
Hall67 USA MMAS 
questionnaire 
Self-reported, 
NDI 
1,165 40-70 CVD 
incidenc
e/ 1000 
person 
years* 
 
11.4 (8.9-14.5) 
16.6 (11.9-23.2) 18.6 (13.8-25.0) 
Kupelian
68 
USA MMAS 
questionnaire 
Self-reported, 
NDI 
928 40-70 MS 1.35 (1.01-1.81) 1.2 (0.8-1.8) 1.5 (1.0-2.2) 
Banks64 Australia MMAS 
questionnaire 
Self-reported 95,038 ≥45 IHD 1.08 (0.92-1.27) 1.4 (1.2-1.6) 1.6 (1.3-2.0) 
HF 5.19 (1.75-15.4) 5.4 (1.8-16.2) 8.0 (2.6-24.2) 
Stroke 1.01 (0.75-1.37) 1.9 (1.4-2.5) 1.3 (0.9-1.9) 
PVD 0.93 (0.54-1.60) 1.2 (0.7-2.1) 1.9 (1.1-3.3) 
All 
CVD 
0.99 (0.90-1.09) 1.2 (1.1-1.4) 1.4 (1.2-1.5) 
Schouten
70 
The 
Netherlands 
ICS5 GP records 1,248 50-75 CV 
event 
incidenc
e/ 100 
person 
years** 
5.1 (4.2-6.1) 10.1 (7.4-13.8) 19.0 (11.5-31.5) 
Morillo35 Colombia, 
Ecuador, 
Venezuela 
MMAS 
questionnaire 
Self-reported 1,946 ≥40  
ED 
 
 
 
 
 
      Colombia Ecuador  
Venezuela 
 
 
 
  
       Mild Mod Sev Mild Mod Sev Mild Mod Sev 
      DM 0.6 (0.2-
1.4) 
5.1 
(2.3-
11.0
)* 
1.9 (0-
7.7) 
1.1 
(0.6-
2.2) 
1.7 
(0.8-
3.6) 
2.1 (0-
8.6) 
1.0 (0.6-
1.9) 
3.3 (1.8-6.2)* 3.1 
(1.2-
8.3)* 
      HTN 1.1 (0.7-
1.7) 
2.2 
(1.4-
3.6) 
2.4 
(1.1-
5.4) 
1.5 
(0.9-
2.5) 
1.6 
(0.9-
2.9) 
2.5 
(0.8-
7.6) 
1.3 (0.9-
1.8) 
1.9 (1.2-3.0) 2.3 
(1.1-
4.8) 
      IHD 0.6 (0.3-
1.3) 
2.4 
(1.2-
4.9)
* 
2.1 
(0.6-
6.9) 
1.5 
(0.7-
3.2) 
0.6 
(0.2-
1.9) 
3.1 (0-
12.8) 
1.1 (0.6-
1.8) 
5.0 (2.9-8.7)* 0.7 
(0-
2.8) 
Rosen49 USA, UK, 
Germany, 
France, Italy, 
Spain, 
Mexico, and 
Brazil 
 
Questionnaire3 Physician 
diagnosis or 
under treatment 
27,839 20-75 CVD % No ED ED 
HTN** 19 36 
Angina** 7 17 
HCL** 16 29 
DM** 4 14 
Lahoz62 Spain IIEF-5 Self-reported, 
ABPI, Carotid 
Doppler 
614 45-74 CVD% No ED ED 
 
DM 7.5 16.9* 
 
HTN 34.0 42.1 
 
HCL 43.6 49.9 
 
CVD 6.3 13.7* 
 
MS 38.9 44.3 
 
Cholesterol (SD) 203 (35) 193 (39)* 
 
Triglycerides (SD) 126 (14) 129 (16) 
 
ABPI <0.9 2.5 (0.3-4.6) 4.3 (2.0-6.4) 
 
Carotid plaques 44.8 (38.3-51.2) 63.8 (58.7-68.8)* 
 
Mak25 Belgium IIEF & 
Questionnaire4 
Self-reported 799 40-70  40-49 years 50-59 years 60-69 years 
      HTN 0.9 (0.3-2.3) 1.5 (0.9-2.5) 2.4 (1.4-3.9) 
      DM 7.0 (1.0-51.3) 1.8 (0.8-3.8) 1.2 (0.6-2.3) 
      CVD 0.7 (0.2-2.2) 2.1 (1.1-3.7) 2.3 (1.4-3.8) 
CVD (cardiovascular disease), HTN (hypertension), DM (diabetes mellitus) IHD (ischaemic heart disease), PVD (peripheral vascular disease), MS (metabolic syndrome), HF (heart failure), HCL 
(hypercholesterolaemia), TG (triglycerides), ABPI (ankle-brachial pressure index), MI (myocardial infarction), NDI (National Death Index). *p<0.05 **p<0.001 
1 Chinese Index of Erectile Function  
2 Questionnaire: participants screened with 'difficulty getting or keeping an erection 1. never had it, 2. had it before but not now, 3. have it now sometimes, 4. have it now always’, 
subsequently confirmed by IIEF.  
3 Questionnaire: Erection difficulties? ‘ (A) seen a doctor, pharmacist or therapist about it; (B) tried any kind of remedy, with or without prescription; (C) not done anything about it; or (D) never 
had it.’ 
4 IIEF used in sexually active men; IIEF item 15 was used as a surrogate measure for men not sexually active in past one month: ‘how do you rate your confidence that you could get and keep an 
erection? Very high confidence= no ED, high confidence most times= mild ED, mod-low confidence= moderate ED, very low/ never achieving =complete ED’ 
5 International Continence Society Male Sex Questionnaire: “Do you get erections?” were recoded “ED” if the participants reported “yes, with reduced rigidity” or “yes with severely reduced 
rigidity” or “no, no erections possible” or “no, never had.” 
     
 
 
 
 
 
 
 
 
Table 5. The Association between ED and Benign Prostatic Hyperplasia 
*p<0.05 **p<0.01 ***p<0.001 
1 International Continence Society Male Sex Questionnaire: “Do you get erections?” were recoded “ED” if the participants reported “yes, with reduced rigidity” or “yes with severely reduced 
rigidity” or “no, no erections possible” or “no, never had.” 
2 Questionnaire: participants screened with 'difficulty getting or keeping an erection 1. never had it, 2. had it before but not now, 3. have it now sometimes, 4. have it now always’, 
subsequently confirmed by IIEF.  
3 International Prostate Symptom Score: points based 8-item questionnaire on lower urinary tract symptoms and quality of life. Mild= 1-7, moderate= 8-19, severe ≥20 
4American Urological Association Symptom Index: points based 7-item questionnaire on lower urinary tract symptoms. Identical to IPSS except for quality of life item. Mild= 1-7, moderate= 8-
19, severe ≥20
Author Country ED measurement BPH measurement Study size Age (years) Findings [OR/ HR 95% Confidence Intervals 
or Prevalence (%)] 
Zhang71 China IIEF-5 Self-reported 5,210 ≥40 1.332 (1.284-1.521)* 
Mariappan17 Malaysia IIEF-5 AUA symptom index4 353 ≥40 1.4 (1.3-1.6) p=0.064 
Shabsigh61 USA, UK, France, 
Germany, Italy, Spain 
IIEF & Questionnaire2 Self-reported 28,691 20-75 2.0 (1.8-2.5) 
Moreira73 Brazil MMAS questionnaire Self-reported 654 40-70 3.67 (1.17-11.48)* 
Morillo35 Colombia, Ecuador, 
Venezuela 
MMAS questionnaire Self-reported 1,946 ≥40 1.5 (1.0 – 2.1) 
Korneyev22 Russia IIEF IPSS 1,083 20-77 4.10 (3.16-5.33) 
Kok73 The Netherlands ICS1 IPSS3 3,924 50-78 1.600 (1.176-2.175)** 
Akkus32 Turkey MMAS questionnaire IPSS 1,982 ≥40 Moderate LUTS Severe LUTS 
4.41 (3.29-5.90)** 6.24 (3.43-11.35) 
Moreira30 Brazil MMAS questionnaire IPSS 602 40-70 Moderate LUTS Severe LUTS 
2.14 (1.26–2.63)** 5.86 (2.82 – 
12.17)*** 
Laumann31 USA MMAS questionnaire IPSS 2,173 ≥40 Moderate LUTS Severe LUTS 
1.7 (1.0-2.6) 6.0 (1.9-19.0) 
Glasser74 USA MMAS questionnaire IPSS 2,173 ≥40 Mild LUTS (%) Moderate LUTS 
22 40 
Kim72 South Korea MMAS questionnaire IPSS variant 1,842 ≥40 % ED & LUTS % ED, no LUTS*** 
99 1 
 
